Steele R W, Keeney R E, Brown J, Young E J
J Infect Dis. 1977 Apr;135(4):593-9. doi: 10.1093/infdis/135.4.593.
Thirteen patients severely infected with herpesvirus were treated with intravenous adenine arabinoside (ara-A), and two patients received placebo therapy. Blastogenic and cytotoxic responses specific for the virus infecting each patient were determined before, during, and after treatment. Blastogenic responses to three mitogens (phytohemagglutinin, pokeweed, and concanavalin-A) were examined, as were titers of viral antibody. In vitro responses during and after treatment with ara-A were unchanged or often enhanced as compared with values before treatment. Newborn infants, presumably infected at or shortly before birth, did not demonstrate cellular immune reactivity to the infecting virus until after four days of life. In this series of patients, prognosis appeared to be in part determined by the cellular immune competence of the host at the time of infection.
13名严重感染疱疹病毒的患者接受了静脉注射阿糖腺苷(ara - A)治疗,2名患者接受了安慰剂治疗。在治疗前、治疗期间和治疗后,测定了针对感染每位患者的病毒的增殖反应和细胞毒性反应。检测了对三种有丝分裂原(植物血凝素、商陆和刀豆球蛋白A)的增殖反应以及病毒抗体滴度。与治疗前的值相比,ara - A治疗期间和治疗后的体外反应未发生变化或常常增强。推测在出生时或出生前不久感染的新生儿,直到出生四天后才表现出对感染病毒的细胞免疫反应性。在这组患者中,预后似乎部分取决于感染时宿主的细胞免疫能力。